

Resource Summary Report

Generated by [dkNET](#) on Aug 4, 2026

Brilliant Violet 650(TM) anti-human CD8

RRID:AB_2564509

Type: Antibody

Proper Citation

BioLegend Cat# 344729, RRID:AB_2564509

Antibody Information

URL: http://antibodyregistry.org/AB_2564509

Proper Citation: BioLegend Cat# 344729, RRID:AB_2564509

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2564509

Vendor: BioLegend

Catalog Number: 344729

Alternative Catalog Numbers: 344730

Record Creation Time: 20250820T033130+0000

Record Last Update: 20250820T162910+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 650(TM) anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Martin A, et al. (2025) IFN- γ licenses normal and pathogenic ALPK1/TIFA pathway in human monocytes. iScience, 28(1), 111563.

Jain J, et al. (2024) Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice. iScience, 27(12), 111470.

Keenan BP, et al. (2022) Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell reports, 40(12), 111384.

Qadir AS, et al. (2021) CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. iScience, 24(11), 103348.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell, 39(12), 1623.